GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenxbio Inc (NAS:RGNX) » Definitions » Cyclically Adjusted PS Ratio

Regenxbio (Regenxbio) Cyclically Adjusted PS Ratio : 4.62 (As of May. 29, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Regenxbio Cyclically Adjusted PS Ratio?

As of today (2024-05-29), Regenxbio's current share price is $14.97. Regenxbio's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $3.24. Regenxbio's Cyclically Adjusted PS Ratio for today is 4.62.

The historical rank and industry rank for Regenxbio's Cyclically Adjusted PS Ratio or its related term are showing as below:

RGNX' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 3.79   Med: 5.09   Max: 7.04
Current: 4.61

During the past years, Regenxbio's highest Cyclically Adjusted PS Ratio was 7.04. The lowest was 3.79. And the median was 5.09.

RGNX's Cyclically Adjusted PS Ratio is ranked better than
55.53% of 506 companies
in the Biotechnology industry
Industry Median: 5.5 vs RGNX: 4.61

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Regenxbio's adjusted revenue per share data for the three months ended in Mar. 2024 was $0.342. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $3.24 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Regenxbio Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Regenxbio's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenxbio Cyclically Adjusted PS Ratio Chart

Regenxbio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 5.56

Regenxbio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 5.56 6.50

Competitive Comparison of Regenxbio's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Regenxbio's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenxbio's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenxbio's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Regenxbio's Cyclically Adjusted PS Ratio falls into.



Regenxbio Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Regenxbio's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=14.97/3.24
=4.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regenxbio's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Regenxbio's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.342/131.7762*131.7762
=0.342

Current CPI (Mar. 2024) = 131.7762.

Regenxbio Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.000 100.560 0.000
201409 0.037 100.428 0.049
201412 0.087 99.070 0.116
201503 0.049 99.621 0.065
201506 0.055 100.684 0.072
201509 0.237 100.392 0.311
201512 0.169 99.792 0.223
201603 0.015 100.470 0.020
201606 0.090 101.688 0.117
201609 0.005 101.861 0.006
201612 0.064 101.863 0.083
201703 0.017 102.862 0.022
201706 0.214 103.349 0.273
201709 0.043 104.136 0.054
201712 0.065 104.011 0.082
201803 3.863 105.290 4.835
201806 1.135 106.317 1.407
201809 0.156 106.507 0.193
201812 1.046 105.998 1.300
201903 0.024 107.251 0.029
201906 0.215 108.070 0.262
201909 0.399 108.329 0.485
201912 0.319 108.420 0.388
202003 0.476 108.902 0.576
202006 0.445 108.767 0.539
202009 2.544 109.815 3.053
202012 0.573 109.897 0.687
202103 0.452 111.754 0.533
202106 0.518 114.631 0.595
202109 0.722 115.734 0.822
202112 8.189 117.630 9.174
202203 0.517 121.301 0.562
202206 0.757 125.017 0.798
202209 0.613 125.227 0.645
202212 0.724 125.222 0.762
202303 0.440 127.348 0.455
202306 0.459 128.729 0.470
202309 0.658 129.860 0.668
202312 0.505 129.419 0.514
202403 0.342 131.776 0.342

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Regenxbio  (NAS:RGNX) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Regenxbio Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Regenxbio's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Regenxbio (Regenxbio) Business Description

Industry
Traded in Other Exchanges
Address
9804 Medical Center Drive, Rockville, MD, USA, 20850
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa).
Executives
Kenneth T. Mills director, officer: See Remarks C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Vittal Vasista officer: See Remarks C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Jennifer Zachary director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Steve Pakola officer: Chief Medical Officer C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Allan M. Fox director, 10 percent owner C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Jean Bennett director C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
George V Migausky director C/O DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Patrick J. Christmas officer: Senior VP, General Counsel C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Curran Simpson officer: SVP of Technical Operations C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Hayden Donald J Jr director C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Olivier Danos officer: Chief Scientific Officer C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Luke M Beshar director 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Stephen Yoo officer: Chief Medical Officer C/O REGENXBIO INC,, 9600 BLACKWELL ROAD, SUITE 210, ROCKVILLE MD 20850
Alexandra Glucksmann director C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Daniel Tasse director C/O IKARIA, INC., 6 STATE ROUTE 173, CLINTON NJ 08809